T2 Biosystems, Inc. TTOO shares experienced a decline on Tuesday as the stock pulled back after its strong performance on Monday. This pullback occurred after the FDA cleared T2 Biosystems’ biothreat panel for commercial distribution. You can read more about this clearance on Benzinga.
What To Know: On Monday, T2 Biosystems’ stock received a boost following the FDA clearance, allowing the company to market and sell the T2Biothreat Panel, a direct-from-blood molecular diagnostic test, in the U.S. market.
However, T2 Biosystems’ stock experienced a decline of over 26% on Tuesday, offsetting the gains made on Monday.
Related Link: What’s Going On With Intel Stock?
TTOO Price Action: According to Benzinga Pro, TTOO shares were gaining back 5.3% in the after-hours session and trading at 39 cents.
